Phase II for LymphoStat-B

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Phase II for LymphoStat-B

Postby cheerleader » Wed May 28, 2008 5:22 pm

A lupus medication fast-tracked for MS- more B cell activity....

LymphoStat-B® (belamumab) is a human monoclonal antibody that inhibits the biological activity of B-lymphocyte stimulator, or BLyS®. BLyS is a naturally occurring protein discovered by HGS. In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.

Human Genome Sciences today also announced that HGS and GSK have agreed to initiate a Phase 2 trial of LymphoStat-B for use in the treatment of multiple sclerosis (MS). Patients with MS continue to have unmet medical needs despite the treatments currently available. The scientific rationale for testing LymphoStat-B in MS is strong, since the drug acts by inhibiting the activity of BLyS(TM), a protein discovered by HGS, which is found at elevated levels in MS lesions and is associated with the MS disease process. In addition, the results of a Phase 2 trial of rituximab provided clinical validation for B-cell modulation in the treatment of relapsing-remitting MS. ... 56795.html
Husband dx RRMS 3/07
dx dual jugular vein stenosis (CCSVI) 4/09
User avatar
Family Elder
Posts: 5290
Joined: Mon Sep 10, 2007 2:00 pm
Location: southern California


Return to Drug Pipeline


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service